Johnny Yap

https://assets.montefioreeinstein.org/profiles/images/physphoto/Yap_Johnny_MD_420x504-2.jpg

First Name

Johnny

Last Name

Yap

NPI

1790766269

Faculty ID

17426

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Utilizing a broad range of radiation treatment technologies.

Research Focus

Breast cancer.

Elsevier Profile

EMR ID

113299

Biography

<p>Johnny Yap, MD, is a Radiation Oncologist and Assistant Professor, Radiation Oncology at Montefiore Einstein. With a clinical focus is in breast, gastrointestinal, gynecological, lung and stereotactic radiation, Dr. Yap has expertise with utilizing a broad range of radiation treatment technologies.</p><p>After earning his Doctor of Medicine at Rosalind Franklin University, Chicago Medical School in 1995, Dr. Yap completed his internship at Yale University in 1996, followed by his radiation oncology residency at Wayne State University Medical Center, Detroit Medical Center in 2000.</p><p>Dr. Yap&rsquo;s research interests focus on breast cancer. His work has been shared in peer-reviewed journals as well as posters, abstracts and oral presentations. Dr. Yap is also an editorial board member and reviewer for <em>Journal of Gastrointestinal Oncology</em>.</p><p>Dr. Yap is board certified by the American Board of Radiology and is a member of the American Society of Radiation Oncology and the Radiosurgery Society.</p>

Is Open Scheduling

Off

Justin Y. K. Tang

https://assets.montefioreeinstein.org/profiles/images/physphoto/Tang_Justin_MD_420x504.jpg

First Name

Justin

Last Name

Tang

NPI

1619385747

Faculty ID

16500

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

56697

Is Open Scheduling

Off

Melissa R. Stein

https://assets.montefioreeinstein.org/profiles/images/physphoto/Stein_Melissa_MD_LC_2013_06-18.jpg

First Name

Melissa

Last Name

Stein

NPI

1699865592

Faculty ID

9444

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Current Investigations</strong></p>

<ol start="1" style=" margin-bottom: 0in;" type="1">
<li>Development of an Objective Structured Clinical Examination (OSCE) in Substance Abuse</li>
</ol>

<p>&#160;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4263

Is Open Scheduling

Off

Nitin Ohri

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/4a5e97b0-c3cc-11eb-a1b3-af964b18991d.jpg

First Name

Nitin

Last Name

Ohri

NPI

1346499431

Faculty ID

13388

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Treating lung and gastrointestinal cancers.

Research Focus

Incorporating novel imaging metrics in the implementation of radiotherapy for non-small cell lung cancer, understanding how physical activity data can be leveraged to enhance the value of cancer care, and exploring novel combinations of immunotherapy and radiotherapy.

Elsevier Profile

EMR ID

5629

Biography

<p>Nitin Ohri, MD, MS, is Professor, Radiation Oncology at Montefiore Einstein. He is a radiation oncologist with a clinical focus on treating lung and gastrointestinal cancers.</p><p>After completing his Bachelor of Science in biomedical engineering at Columbia University in 2003, Dr. Ohri earned his Doctor of Medicine from Washington University in 2007. He then completed an internship in internal medicine at Barnes-Jewish Hospital in 2008 and then participated in a radiation oncology residency at Thomas Jefferson University, completing it in 2012. Dr. Ohri earned his Master's degree from the Clinical Research Training Program at Montefiore Einstein in 2015.</p><p>Building on his clinical focus, Dr. Ohri&rsquo;s research focuses on incorporating novel imaging metrics in the implementation of radiotherapy for non-small cell lung cancer, understanding how physical activity data can be leveraged to enhance the value of cancer care, and exploring novel combinations of immunotherapy and radiotherapy. Dr. Ohri has designed numerous ongoing and completed investigator-initiated trials that test novel functional imaging-based radiotherapy delivery strategies and new combinations of immunotherapy and radiotherapy. He is also leading a series of trials incorporating continuous activity monitoring with wearable devices into the care of cancer patients. The unifying theme of his work is leveraging novel forms of multidimensional data to improve cancer care, and his work has been presented in many peer-reviewed publications and abstracts. Dr. Ohri is a reviewer for multiple journals, such as the <em>International Journal of Radiation Oncology, Biology, Physics</em>, the <em>American Journal of Clinical Oncology</em> and <em>Journal of the National Cancer Institute</em>.</p><p>Dr. Ohri is board certified in Radiation Oncology by the American Board of Radiology and is a member of the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Association for Cancer Research. He has won multiple awards, including numerous &ldquo;Outstanding Reviewer&rdquo; Awards from the <em>International Journal of Radiation Oncology, Biology, Physics</em>, the Cancer Care Delivery Research Pilot Project Award from NRG Oncology and the Fellowship Award from the Empire Clinical Research Investigator Program.</p>

Is Open Scheduling

Off

Keyur J. Mehta

https://assets.montefioreeinstein.org/profiles/images/physphoto/Mehta_Keyur_MD_420x504-2.jpg

First Name

Keyur

Last Name

Mehta

NPI

1235339326

Faculty ID

12249

CMO Specialties

Clinical Terms

Employment Status

Voluntary

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4466

Is Open Scheduling

Off

Shalom Kalnicki

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/89820450-b883-11ee-8618-fda8dc77c52b.jpg

First Name

Shalom

Last Name

Kalnicki

NPI

1942381371

Faculty ID

9551

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Kalnicki, a radiation oncologist, focuses on new technologies in the radiation treatment of cancer. He was a pioneer in the use of intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), target motion management with 4-D radiation planning, and functional tumor imaging with PET-CT (positron emission tomography &ndash; CAT scan) fusion techniques. Another area of interest is the use of stereotactic guidance in radiation treatment, specifically for stereotactic radiosurgery (SRS). All enhance precision of tumor targeting with radiation therapy, increasing dose to the tumor, while sparing surrounding normal tissues.<br />&nbsp;<br />Dr. Kalnicki's research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies. His clinical interests focus on head and neck, prostate, and breast cancers.</p>

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Kalnicki focuses on researching and implementing new technologies in the radiation treatment of cancer, with the aim of enhancing the dose to the tumor target while preserving normal tissues from radiation injury, potentially increasing tumor control and improving quality of life. His research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Radiation Oncology

Research Focus

An active researcher, Dr. Kalnicki is currently investigating innovative methods of radiation planning and delivery, including Intensity Modulated Radiation Therapy (IMRT), PET-CT fusion for radiation planning, 4-D treatment planning, target motion manage

Elsevier Profile

EMR ID

4214

Biography

<p>Dr. Kalnicki focuses on researching and implementing new technologies in the radiation treatment of cancer, with the aim of enhancing the dose to the tumor target while preserving normal tissues from radiation injury, potentially increasing tumor control and improving quality of life. He pioneered the use of intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), target motion management with 4-D radiation planning, stereotactic body radiation therapy (SBRT) and functional tumor imaging with PET-CT (positron emission tomography &ndash; CAT scan) fusion techniques. His research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies.</p><p>Dr. Kalnicki earned his medical degree at the University of Sao Paulo Medical School in Sao Paulo, Brazil. He completed his residency and fellowship in radiotherapy at Montefiore and Albert Einstein College of Medicine. He came to Montefiore and Einstein from the University of Pittsburgh, School of Medicine, where he was Vice Chairman for Clinical Affairs and Director of Radiation Oncology at the University of Pittsburgh Cancer Institute. </p><p>Prior to joining the University of Pittsburgh Cancer Institute, Dr. Kalnicki served as Chairman of the Department of Radiation Oncology at Allegheny University of Health Sciences in Pittsburgh. He is a member of many prominent professional societies. He has authored numerous articles and abstracts during his career and is a recipient of several awards, including the Fellowship Award from the American College of Radiation Oncology.</p>

Is Open Scheduling

Off

Rafi Kabarriti

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/05986ec0-4373-11ee-9d6f-374ce67539f5.jpg

First Name

Rafi

Last Name

Kabarriti

NPI

1811200256

Faculty ID

15596

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Rafi Kabarriti, MD, is a cum laude graduate of Columbia University with a bachelor&rsquo;s degree in biochemistry and economics.&nbsp;&nbsp;He earned his medical degree at Albert Einstein College of Medicine and completed an internship in internal medicine at Mount Sinai St. Luke's and Mount Sinai West Hospital and a residency in radiation oncology at Montefiore Medical Center, where he was chief resident in the Department of Radiation Oncology.&nbsp;&nbsp;Dr. Kabarriti is the recipient of the prestigious American Society of Clinical Oncology and Conquer Cancer Foundation Young Investigator Award, Empire Clinical Research Investigator Program Fellowship and AIDS Malignancy Consortium fellowship Award.&nbsp;&nbsp;He is also funded by the NIH K12 Paul Calabresi Career Development Award for Clinical Oncology.&nbsp;&nbsp;His research has been selected for oral presentations at national and international meetings including the annual meetings of the American Society for Radiation Oncology, European Society for Radiotherapy, and the European ORL-HNS Congress. Dr. Kabarriti is author and co-author of over 40 articles published in peer-reviewed journals including the Journal of Clinical Oncology, International Journal of Radiation Oncology, Biology, and Physics, Oral Oncology and Head and Neck.&nbsp;His research focus is on optimizing radiation therapy for head and neck and gastrointestinal cancers and combining radiation therapy with novel therapeutics and immunotherapy to improve outcomes for these patients.&nbsp;&nbsp;He is the principal investigator of multiple clinical trials including investigator-initiated clinical trials as well as the local PI on cooperative and international studies.&nbsp;&nbsp;&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Treatment of head and neck, gastrointestinal and other cancer types, and use of advanced technologies in radiation oncology including image guidance, stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS).

Research Focus

Novel therapeutics for the monitoring and management of radiation-induced toxicities using the liver as a model; Integration of radiation therapy with immunotherapy agents to produce a strong anti-tumor systemic immune response.

Elsevier Profile

Selected Publications

<h3>Selected Publications:</h3>
<p>1. &nbsp;<strong>Kabarriti, R</strong>. Ohri, N. Hannan, R. Tishbi, N.&nbsp;Baliga, S. McGovern, KP. Mourad, WF.&nbsp;Ghavamian, R. Kalnicki, S. Guha, C. Garg, MK. PSA Decline During Salvage Radiation Therapy Following Prostatectomy Is Associated With Reduced Biochemical Failure.&nbsp;&nbsp;Practical Radiation Oncology, 2014 Feb 21. &nbsp;</p>
<p>2.&nbsp;&nbsp;<strong>Kabarriti, R</strong>. Guha, C. Hedgehog Signaling and Radiation Induced Liver Injury: A Delicate Balance.&nbsp;&nbsp;Hepatology International, 2014 Jul;8(3):316-20.</p>
<p>3.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Mark D, Fox J, Kalnicki S, Garg MK.&nbsp;Proton therapy for the treatment of pediatric head and neck cancers: A review. Int J Pediatr Otorhinolaryngol. 2016 Jan;79(12)</p>
<p>4. &nbsp;<strong>Kabarriti R</strong>, Quinn TJ, Ewart MR, Mehta KJ, Lomita C, Geller DS, Kalnicki S, Fox JL. Neoadjuvant radiation therapy for the management of myoepithelial carcinoma of the upper extremity. Int J Cancer. 2018 Feb 15;142(4), PMCID: PMC6200873</p>
<p>5.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Bontempo A, Romano M, McGovern KP, Asaro A, Viswanathan S, Kalnicki S, Garg MK. The Impact of Dietary Regimen Compliance on Outcomes for HNSCC Patients Treated with Radiation Therapy. Supportive Care in Cancer, 2018 Sep;26(9):3307-3313; PMID: 29671062</p>
<p>6. &nbsp;Ohri N,&nbsp;<strong>Kabarriti R</strong>, Kaubisch A, Guha C. RFA versus SBRT for HCC: Caution when Interpreting Observational Data; Journal of Clinical Oncology, 2018 Aug 20;36(24):2558; PMID: 29945527</p>
<p>7. &nbsp;Baliga S*,&nbsp;<strong>Kabarriti R*</strong>, Jiang J, Mehta V, Guha C, Kalnicki S, Smith RV, Garg, MK. Utilization of Transoral Robotic Surgery (TORS) in Patients with Oropharyngeal Squamous Cell Carcinoma and its impact on Survival and use of Chemotherapy.&nbsp;&nbsp;Oral Oncology, 2018 Nov;86:75-80; PMID: 30409323&nbsp;&nbsp;&nbsp;*co-first author</p>
<p>8. &nbsp;Brodin NP,&nbsp;<strong>Kabarriti R</strong>, Pankuch M, Schechter CB, Gondi V, Kalnicki S, Guha C, Garg MK, Tom&eacute; WA.&nbsp;&nbsp;A Quantitative Clinical Decision-support Strategy Identifying Which Oropharyngeal Head and Neck Cancer Patients may Benefit the Most from Proton Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 Nov 26.&nbsp;&nbsp;PMID: 30496877</p>
<p>9. &nbsp;Barahman M, Asp P, Roy-Chowdhury N, Kinkhabwala M, Roy-Chowdhury J,&nbsp;<strong>Kabarriti R</strong>, Guha C.&nbsp;&nbsp;Hepatocyte Transplantation: Quo Vadis? Int J Radiat Oncol Biol Phys. 2018 Nov 29.&nbsp;&nbsp;PMID: 30503786</p>
<p>10.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Brodin NP, Lundgren G, Ohri N, Tom&eacute;, WA, Kalnicki S, Garg MK. Early Response Assessment on Mid-Treatment CT Predicts Loco-Regional Recurrence in Oropharyngeal Cancer Patients Treated with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1036-1045; PMID: 29779936</p>
<p>11.&nbsp;<strong>Kabarriti R</strong>, Baliga S, Ohri N, Guha C, Kalnicki S, Garg, MK. Radiotherapy for Patients With Newly Diagnosed Metastatic Head and Neck Squamous Cell Carcinoma.&nbsp;&nbsp;Head and Neck, 2018 Dec 16.&nbsp;&nbsp;PMID: 30556318</p>
<p>12. &nbsp;Barahman M, Zhang W, Yaffe Harris H, Aiyer A,&nbsp;<strong>Kabarriti R</strong>, Kinkhabwala M, Roy-Chowdhury N, Beck AP, Scanlan TS, Roy-Chowdhury J, Asp P, Guha C. Radiation-primed hepatocyte transplantation in murine monogeneic dyslipidemia normalizes cholesterol and prevents atherosclerosis.&nbsp;&nbsp;J Hepatol. 2019 Jan 14.&nbsp;&nbsp;PMID: 30654068</p>
<p>13.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Brodin NP, Ahmed S, Vogelius I, Guha C, Kalnicki S, Tom&eacute; WA, Garg MK.&nbsp;&nbsp;Origin of Locoregional Recurrences After Definitive Intensity-modulated Radiation Therapy (IMRT) for Laryngeal Cancer Determined Based on Follow-up PET/CT Imaging.&nbsp;&nbsp;Cureus. 2019 Jan 8;11(1):e3856; PMID: 30899607</p>
<p>14. &nbsp;Jiang JM, Ohri N, Tang J, Moadel R, Cynamon J, Kaubisch A, Kinkhabwala M, Garg MK, Guha C,&nbsp;<strong>Kabarriti R</strong>.&nbsp;&nbsp;Centers with More Therapeutic Modalities are Associated with Improved Outcomes for Patients with Hepatocellular Carcinoma.&nbsp;&nbsp;Journal of Gastrointestinal Oncology, 2019 Jun;10(3):546-553. PMID: 31183206</p>
<p>15.&nbsp;&nbsp;<strong>Kabarriti R</strong>, Brodin NP, Ohri N, Narang R, Huang R, Chuy JW, Rajdev LN, Kalnicki S, Guha C, Garg MK.&nbsp;&nbsp;Human Papillomavirus, Radiation Dose and Survival of Patients with Anal Cancer. Acta Oncolgica, 2019 Jul 8:1-7, PMID: 31282249</p>
<p>16. &nbsp;Zhu S, Brodin NP, English K, Ohri N, Chuy JW, Rajdev LN, Narang R, Kalnicki S, Guha C, Garg MK,&nbsp;<strong>Kabarriti R. &nbsp;</strong>Comparing Outcomes Following Total Neoadjuvant Therapy and Following Neoadjuvant Chemoradiation Therapy in Patients with Locally Advanced Rectal Cancer.&nbsp;EClinicalMedicine, in Press</p>

EMR ID

54490

Biography

<p class="MsoNormal">Rafi Kabarriti, MD, is a cum laude graduate of Columbia University with a bachelor&rsquo;s degree in biochemistry and economics.</p><p class="MsoNormal">Dr. Kabarriti earned his medical degree at Albert Einstein College of Medicine and completed a residency in internal medicine at St. Luke&rsquo;s-Roosevelt Hospital Center and a residency in radiation oncology at Montefiore Medical Center, where he was chief resident in the Department of Radiation Oncology.</p><p class="MsoNormal">Dr.Kabarriti is the recipient of the 2014 Young Investigator Award given by the Conquer Cancer Foundation and the American Society of Clinical Oncology. In addition, his abstracts have been selected for oral presentations at national and international meetings including the annual meetings of the American Society for Radiation Oncology. Dr. Kabarriti is author and co-author of articles published in peer-reviewed journals including <i>the International Journal of Radiation Oncology</i><i>&bull;Biology</i><i>&bull;Physics</i>, <i>Hepatology International</i>, and <i>PLoS One</i>.</p>

Is Open Scheduling

Off

Chandan Guha

https://assets.montefioreeinstein.org/profiles/images/physphoto/Guha_Chandan_MD_420x504.jpg

First Name

Chandan

Last Name

Guha

NPI

1093917924

Faculty ID

7020

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Exploring therapeutic potential of stem cell regeneration in the event of radiation insult </strong><br />Exposure to high doses of ionizing radiation in the event of therapeutic, accidental or intentional incident such as nuclear/radiological warfare can lead to debilitating injuries to multiple organs resulting in death within days depending on the amount of radiation dose and the quality of radiation. Unfortunately, there is not a single FDA-licensed drug approved against acute radiation injury.</p>
<p>Radiation damage to multiple organs often described as multiple organ dysfunction syndrome (MODS) or acute radiation syndrome (ARS) results from rapid depletion of radiosensitive cells, these cells are usually the stem or progenitor cells with high proliferative capacity; naturally, bone marrow stem cells (BMSC), and intestinal stem cells (ISC), which are extremely critical in maintaining a pool of peripheral blood cells and in maintaining villi for the absorption of nutrients are highly sensitive to radiation. One of the most efficient ways of rescuing MODS is to administer fresh cells that can repair, support and/or replace the damaged cells and repopulate the damaged tissue with healthy cells. The Rad-Stem Center for Medical Countermeasures against Radiation (RadStem CMCR) program at Einstein is developing stem cell-based therapies to treat acute radiation syndrome (ARS) that results from radiation injury.</p>
<p>Radiation-induced gastrointestinal syndrome (RIGS) results from a combination of direct damage to intestinal crypt and endothelial cells, and subsequent loss of the mucosal barrier leading to microbial infection, septic shock and systemic inflammatory response syndrome (SIRS). Currently, there is no treatment for RIGS in clinic. Irradiation induces apoptosis of crypt ISC, endothelial cells and enterocytes within hours. Acute loss of cells in situ requires rapid compensation of their functions and this is best achieved using cell replacement therapies. We are interested in exploring intestinal regenerative therapy with a combination of systemic administration of growth factors and cell replacement therapy to salvage Gl function post-radiation exposure. We are testing combinations of: a) intestinal stem cell growth factor, R-spondinl (R-spol), b) TLR ligands, and c) transplantation of bone marrow-derived endothelial progenitor cells (EPC) and mesenchymal stem cells (MSC) to restore IR-damaged ISC niche, protect against IR-induced cell death and provide growth signals for host ISC regeneration, thus providing protection and mitigation from RIGS.</p>
<p><strong>Preparative live irradiation for hepatocyte transplant in acute liver injury and cirrhosis </strong><br />Hepatocyte transplantation (HT) is a very attractive alternative to liver transplant in the treatment of both inherited and acquired liver diseases. However, benefits of this procedure are currently limited by the inability of the transplanted hepatocytes to proliferate in the host liver, and lack of a noninvasive method to evaluate the repopulation of transplanted hepatocytes in the liver. In order to develop a clinically feasible protocol for HT, we are exploring preparative hepatic irradiation (HIR) for liver repopulation (in place of liver transplant) to deplete host hepatocytes and permit preferential proliferation of the engrafted donor cells in response to hepatic mitotic stimuli.<strong> &nbsp;</strong>Our lab was the first one to demonstrate that preparative HIR and partial hepatectomy (PH), followed by HT results in the replacement of virtually all host hepatocytes by the transplanted non-irradiated hepatocytes in 12 weeks. We are interested in using inducible pluripotent stem cells (iPSC)- derived hepatocytes following highly focused irradiation of the damaged liver in place of a liver transplant. We are also interested in exploring non-invasive biomarkers to validate that the transplanted hepatocytes can efficiently replace host hepatocytes upon liver irradiation.</p>
<p><strong>Cancer Immunotherapy </strong><br />Radiation therapy (RT) has been used as a standard treatment modality for many solid tumors. While tumoricidal properties of RT are instrumental for standard clinical application, irradiated tumors can potentially serve as a source of tumor antigens <em>in vivo</em>, where dying tumor cells would release various tumor antigens slowly over time. Using different<em> in vitro</em> and <em>in vivo</em> tumor models we, and others, demonstrated that RT enhances oxidative stress, and augments the release of necessary activating signals for DC such as endogenous danger associated molecular pattern (DAMP) molecules from irradiated cells. These RT-mediated processes lead to an increase antigenecity of irradiated cells which augments antigen presentation leading to an effective anti-tumoral immune responses. However the underlying mechanism of this processes has still to be determined.</p>
<p>Over the last years we have been interested in designing novel tumor vaccines that amplify the tumor immune response using conventional and exploratory cancer therapies. In particular we are focusing on evaluating the immunogenic properties of radiation therapies and determine how immunotherapeutic molecules can synergize with RT in boosting immune cells cell function. We are also interested in exploring therapeutic effect of ultrasound therapy in the treatment of solid tumor. Our recent work on use of Listeria-based vaccine therapy in combination of RT shows that this strategy is more effective than RT alone.</p>

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Guha is a radiation oncologist who specializes in prostate, genitourinary, liver and GI malignancies, and radio surgery. His research interests include development of stem-cell based therapies to treat radiation-induced toxicity and prevent death in patients.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p><strong>Immunomodulation of radiation therapy: Radiation-enhanced tumor vaccines</strong></p>
<ol>
<li>Ahmed MM, Guha C, Hodge JW, Jaffee E. Immunobiology of Radiotherapy: New Paradigms. Radiat Res. 2014, Aug;182(2):123-5</li>
<li>Almo SC, Guha C. Considerations for Combined Immune Checkpoint Modulation and Radiation Treatment. Radiat Res. 2014, Aug;182(2):230-8</li>
<li>Kawashita Y, Deb NJ, Garg M, Kabarriti R, Alfieri A, Takahashi M, Roy-Chowdhury J, Guha C. An Autologous In Situ Tumor Vaccination Approach for Hepatocellular Carcinoma. Flt3 Ligand Gene Transfer Increases Antitumor Effects of a Radio-Inducible Suicide Gene Therapy in an Ectopic Tumor Model. Radiat Res. 2014 Aug;182(2):201-10</li>
<li>Bernstein, Michael B; Garnett, Charlie T; Zhang, Huogang; Velcich, Anna; Wattenberg, Max M; Gameiro, Sofia R; Kalnicki, Shalom; Hodge, James W; Guha, Chandan. Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer biotherapy &amp; radiopharmaceuticals, 2014 May; 29 (4):153-61</li>
<li>Ahmed MM, Hodge JW, Guha C, Bernhard EJ, Vikram B, Coleman CN. Harnessing the potential of radiation-induced immune modulation for cancer therapy. Cancer Immunol Res. 2013 Nov;1(5):280-4</li>
<li>Gameiro SR, Higgins JP, Dreher MR, Woods DL, Reddy G, Wood BJ, Guha C, Hodge JW. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression. PLoS One. 2013 Jul 24;8(7)</li>
<li>Zhang, Huagang; Liu, Laibin; Yu, Dong; Kandimalla, Ekambar R; Sun, Hui Bin; Agrawal, Sudhir; Guha, Chandan. An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy. PloS one, 2012; 7 (5)</li>
<li>Hannan, Raquibul; Zhang, Huagang; Wallecha, Anu; Singh, Reshma; Liu, Laibin; Cohen, Patrice; Alfieri, Alan; Rothman, John; Guha, Chandan. Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. Cancer immunology, immunotherapy: CII, 2012 Dec; 61 (12):2227-38</li>
</ol>
<p><strong>Stem cell based therapy for radiation injury</strong></p>
<ol>
<li>Benderitter, Marc; Caviggioli, Fabio; Chapel, Alain; Coppes, Robert P; Guha, Chandan; Klinger, Marco; Malard, Olivier; Stewart, Fiona; Tamarat, Radia; Luijk, Peter Van; Limoli, Charles L. Stem Cell Therapies for the Treatment of Radiation-Induced Normal Tissue Side Effects. Antioxidants &amp; redox signaling, 2014, Jul 10;21(2):338-55</li>
<li>Zachman, Derek K; Leon, Ronald P; Das, Prerna; Goldman, Devorah C; Hamlin, Kimberly L; Guha, Chandan; Fleming, William H. Endothelial cells mitigate DNA damage and promote the regeneration of hematopoietic stem cells after radiation injury. Stem cell research, 2013 Nov; 11 (3):1013-21</li>
<li>Saha, Subhrajit; Bhanja, Payel; Liu, Laibin; Alfieri, Alan A; Yu, Dong; Kandimalla, Ekambar R; Agrawal, Sudhir; Guha, Chandan, &lsquo;TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome&rsquo;; PloS one, 2012; 7 (1)</li>
<li>Saha, Subhrajit; Bhanja, Payel; Kabarriti, Rafi; Liu, Laibin; Alfieri, Alan A; Guha, Chandan,. Bone marrow stromal cell transplantation mitigates radiation-induced gastrointestinal syndrome in mice. PloS one, 2011; 6 (9)</li>
<li>Bhanja P, Saha S, Kabarriti R, Liu L, Roy-Chowdhury N, Roy-Chowdhury J, Sellers RS, Alfieri AA, Guha C. Protective role of R-spondin1, an intestinal stem cell growth factor, against radiation-induced gastrointestinal syndrome in mice. PLoS One. 2009 Nov 24;4(11)</li>
</ol>
<p><strong>Preparative irradiation to facilitate liver cell repopulation and stem cell engraftment <em>in vivo</em></strong></p>
<ol>
<li>Vainshtein, Jeffrey M; Kabarriti, Rafi; Mehta, Keyur J; Roy-Chowdhury, Jayanta; Guha, Chandan. Bone Marrow-Derived Stromal Cell Therapy in Cirrhosis: Clinical Evidence, Cellular Mechanisms, and Implications for the Treatment of Hepatocellular Carcinoma. International journal of radiation oncology, biology, physics, 2014 Jul 15; 89 (4):786-803</li>
<li>Vainshtein, Jeffrey M; Kabarriti, Rafi; Mehta, Keyur J; Roy-Chowdhury, Jayanta; Guha, Chandan. Bone Marrow-Derived Stromal Cell Therapy in Cirrhosis: Clinical Evidence, Cellular Mechanisms, and Implications for the Treatment of Hepatocellular Carcinoma. International journal of radiation oncology, biology, physics. 2014 Jul 15; 89 (4):786-803</li>
<li>Yannam, Govardhana Rao; Han, Bing; Setoyama, Kentaro; Yamamoto, Toshiyuki; Ito, Ryotaro; Brooks, Jenna M; Guzman-Lepe, Jorge; Galambos, Csaba; Fong, Jason V; Deutsch, Melvin; Quader, Mubina A; Yamanouchi, Kosho; Kabarriti, Rafi; Mehta, Keyur; Soto-Gutierrez, Alejandro; Roy-Chowdhury, Jayanta; Locker, Joseph; Abe, Michio; Enke, Charles A; Baranowska-Kortylewicz, Janina; Solberg, Timothy D; Guha, Chandan; Fox, Ira J. A nonhuman primate model of human radiation-induced venocclusive liver disease and hepatocyte injury. International journal of radiation oncology, biology, physics, 2014 Feb 1; 88 (2):404-11</li>
<li>Miyazaki, Kensuke; Yamanouchi, Kosho; Sakai, Yusuke; Yamaguchi, Izumi; Takatsuki, Mitsuhisa; Kuroki, Tamotsu; Guha, Chandan; Eguchi, Susumu, &lsquo;Construction of liver tissue in&yacute;&yacute;vivo with preparative partial hepatic irradiation and growth stimulus: investigations of less invasive techniques and progenitor cells&rsquo;; The Journal of surgical research. 2013 Dec; 185 (2):889-95</li>
<li>Puppi, Juliana; Strom, Stephen C; Hughes, Robin D; Bansal, Sanjay; Castell, Jose V; Dagher, Ibrahim; Ellis, Ewa C S; Nowak, Greg; Ericzon, Bo-Goran; Fox, Ira J; Gomez-Lechon, M Jose; Guha, Chandan; Gupta, Sanjeev; Mitry, Ragai R; Ohashi, Kazuo; Ott, Michael; Reid, Lola M; Roy-Chowdhury, Jayanta; Sokal, Etienne; Weber, Anne; Dhawan, Anil, &lsquo;Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in London&rsquo;; Cell transplantation. 2012; 21 (1):1-10</li>
<li>Zhou, Hongchao; Dong, Xinyuan; Kabarriti, Rafi; Chen, Yong; Avsar, Yesim; Wang, Xia; Ding, Jianqiang; Liu, Laibin; Fox, Ira J; Roy-Chowdhury, Jayanta; Roy-Chowdhury, Namita; Guha, Chandan. Single liver lobe repopulation with wildtype hepatocytes using regional hepatic irradiation cures jaundice in Gunn rats. PloS one. 2012; 7 (10)</li>
<li>Ding, Jianqiang; Yannam, Govardhana R; Roy-Chowdhury, Namita; Hidvegi, Tunda; Basma, Hesham; Rennard, Stephen I; Wong, Ronald J; Avsar, Yesim; Guha, Chandan; Perlmutter, David H; Fox, Ira J; Roy-Chowdhury, Jayanta. Spontaneous hepatic repopulation in transgenic mice expressing mutant human &yacute;&yacute;1-antitrypsin by wild-type donor hepatocytes. The Journal of clinical investigation, 2011 May; 121 (5):1930-4</li>
<li>Soltys, Kyle A; Soto-Gutierrez, Alejandro; Nagaya, Masaki; Baskin, Kevin M; Deutsch, Melvin; Ito, Ryotaro; Shneider, Benjamin L; Squires, Robert; Vockley, Jerry; Guha, Chandan; Roy-Chowdhury, Jayanta; Strom, Stephen C; Platt, Jeffrey L; Fox, Ira J. Barriers to the successful treatment of liver disease by hepatocyte transplantation. Journal of hepatology, 2010 Oct; 53 (4):769-74</li>
<li>Dawson, Laura A; Guha, Chandan. Hepatocellular carcinoma: radiation therapy. Cancer journal (Sudbury, Mass.), 2008 Mar-Apr; 14 (2):111-6</li>
<li>Agoni, Lorenzo; Basu, Indranil; Gupta, Seema; Alfieri, Alan; Gambino, Angela; Goldberg, Gary L; Reddy, E Premkumar; Guha, Chandan. Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo. International journal of radiation oncology, biology, physics, 2014 Apr 1; 88 (5):1180-7</li>
</ol>

EMR ID

4049

Is Open Scheduling

Off

David S. Geller

https://assets.montefioreeinstein.org/profiles/images/Geller_David_S_MD_2x.jpg

First Name

David

Last Name

Geller

NPI

1467437764

Faculty ID

10675

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Geller is a full-time faculty member of the Orthopaedic Surgery Department at Montefiore Medical Center and serves as the director of the Orthopaedic Oncology Service, managing both pediatric and adult patients.&nbsp; He is the co-director of Orthopaedic Surgery at the Montefiore Medical Center Moses Campus and currently serves as the Quality Improvement Officer for the Montefiore Cancer Committee.&nbsp; His clinical focus involves primary and metastatic bone and soft tissue tumors, with a secondary interest in joint replacement in the setting of extensive bone loss.&nbsp; He has experience in navigation-guided surgery, allograft reconstruction, endoprosthetic reconstruction, and use of custom or patient-tailored reconstructive prostheses.&nbsp; His research interests include expression patterns in osteosarcoma, surgical margins in osteosarcoma, novel drug screening methods and targeted therapy for osteosarcoma using novel therapeutic modalities.&nbsp; He is extensively involved in resident and medical student education.</p>

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Geller is an orthopaedic surgeon specializing in musculoskeletal oncology and joint replacement, and his practice encompasses adult and pediatric patients. Dr. Geller’s research interests include surface receptor expression in osteosarcoma and potential targeted therapies for the treatment of osteosarcoma. He has developed a novel murine xenograft model for osteosarcoma for the evaluation of surgical margins in osseous tumor surgery. His research additionally includes allograft bone reconstruction techniques, resonance frequency changes during joint reconstruction and pain management in the elderly orthopaedic population.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p>Orthopedic oncology, orthopedic surgery, bone and soft tissue sarcomas, benign bone and soft-tissue tumors, metastatic carcinoma on the bone </p>

Research Focus

<p>Osteosarcoma, with an interest in innovative treatment strategies for both local disease control and metastatic disease; evaluation of expression patterns in osteosarcoma and surgical margins using a xenograft osteosarcoma murine model; the functional role of bone morphogenetic proteins in osteosarcoma surgery; use of intraoperative navigation techniques for tumor surgery; tumorigenesis of osteosarcoma </p>

Elsevier Profile

PubMed.gov URL

Selected Publications

<ul>
<li>Morris J, Dutcher J, <strong>Geller DS</strong>. Revisiting the Orhtopaedic Management of Metastatic Renal Cell Carcinoma: Rationale for a More Aggressive Approach. <em>Current Orthopaedic Practice. </em>2013 Sept/Oct; 24(5):547-551.</li>
<li>Bekarev M, Elsinger EC, Villanueva-Siles E, Borzykowski RM, <strong>Geller DS.</strong> Synovial Sarcoma of the Foot. <em>Journal of Foot and Ankle Surgery</em>. 2013 Jul-Aug; 52(4):513-7. doi: 10.1053</li>
<li>Capogna BM, Lovy A, Blum Y, Kim SJ, Flesen UR, <strong>Geller DS.</strong> Infection Rate Following Total Joint Arthroplasty in the HIV Population. <em>Journal of Arthroplasty</em>. 2013 Sep; 28(8):1254-8. doi: 10.1016</li>
<li>Lall A, Hohn E, Kim M, Gorlick R, Abraham J, <strong>Geller DS</strong>. Comparison of Surface Area Across the Allograft-Host Junction Site Using Conventional and Navigated Osteotomy Technique. <em>Sarcoma</em>. 2012; 2012:197540.&nbsp;</li>
<li>Piperdi S, Austin-Page L, <strong>Geller DS</strong>, Ahluwalia M, Gorlick S, Gill J, Sellers R, Zhang W, Li N, Ching Sohak, Gorlick R. Beta-Catenin Does Not Confer Tumorigenicity when Introduced into Partially Transformed Human Mesenchymal Stem Cells.<em> Sarcoma</em>. 2012. Epub 2012 Oct 18.</li>
<li>Crocco L, Gorlick R,<strong> Geller DS</strong>. Current Practice Management Regarding Thromboembolic Prophylaxis Within the Pediatric Sarcoma Patient Population, <em>Journal of Pediatric Hematology/Oncology</em>.2012 Sep 19. [Epub ahead of print]</li>
<li>&nbsp;Hall GL, Villanueva-Siles E, Borzykowski RM, Gruson KI, Dorfman HD, <strong>Geller</strong> <strong>DS</strong>. Aspergillus osteomyelitis of the proximal humerus: a case report. <em>Skeletal Radiology</em>. 2012 Aug; 41(8):1021-5. Epub 2012 Mar 31.</li>
<li>Sambaziotis C, Plymale M, Lovy A, O&rsquo;Halloran K, McCulloch K, <strong>Geller DS</strong>. Pseudoaneurysm of the Distal Thigh after Manipulation of a Total Knee Arthroplasty. <em>Journal of Arthroplasty</em>. 2012 Aug; 27(7); 1414.</li>
<li>Shakked RJ, <strong>Geller DS</strong>, Gorlick R, Dorfman HD. Mesenchymal chondrosarcoma: Clinicopathologic study of 20 cases. <em>The Archives of Pathology &amp; Laboratory Medicine</em>.&nbsp; 2012 Jan; 136(1):61-75.</li>
<li>Hohn E, Garfein ES, Mehta KJ, <strong>Geller DS. </strong>Quadriceps Tendon Allograft Augmentation after Wide Excision of a Soft Tissue Sarcoma. <em>Current Orthopaedic Practice</em>. 2012 Jan/Feb; 23(1):68-71.</li>
<li>Singh CK, <strong>Geller DS. </strong>The Telescopic Mating Technique for Bulk Allograft Reconstruction. <em>Orthopaedics</em>. 2012 Feb; 35(2):118-124.</li>
<li>Sambaziotis C, Lovy A, Moadel RM, Chamarthy M, Glaser J, Jaini S, Villanueva-Siles E, <strong>Geller DS</strong>. Florine-18 Fluorodeoxyglucose Positron Emission Tomography for Osteochondromas Utilizing a Triple-Time Point Protocol.&nbsp; <em>Open Journal of Medical Imaging</em>. 2011 Dec; 1(2):15-20.</li>
<li>Hassan SE, Bekarev M, Kim MY, Lin J, Piperdi S, Gorlick R, <strong>Geller DS. </strong>Cell Surface Receptor Expression Patterns in Osteosarcoma. <em>Cancer.</em> 2011 Feb 1; 118(3):740-9.</li>
<li>Plymale M, Lovy A, Villanueva-Siles E, <strong>Geller DS.</strong> Isolated intra-articular pseudorheumatoid nodule of the knee.<em> Skeletal Radiology</em>. 2011 Apr; 40(4):463-6.</li>
<li>Green MC, Dorfman HD, Villanueva-Siles E, Gorlick RG, Thornhill BA, Weber RV, <strong>Geller DS. </strong>Aggressively Recurrent Infantile Myofibroma of the Axilla and Shoulder Girdle. A Case Report. <em>Skeletal Radiology</em>.2010 Mar; 40(3):357-61.</li>
<li><strong>Geller DS</strong>, Pope JB, Thornhill BA, Dorfman, HD. Cryptococcal pyarthrosis and sarcoidosis. <em>Skeletal Radiol</em>. 2009 Jul; 38(7):721-7.</li>
<li>Sah A, <strong>Geller DS</strong>, Mankin HJ, Delaney T, Rosenberg A, Wright C, Hornicek FJ. Malignant Transformation of Synovial Chondromatosis of the Shoulder to Chondrosarcoma - A Case Report," <em>Journal of Bone and Joint Surgery. </em>2007 Jun; 89(6):1321-8.</li>
<li><strong>Geller DS</strong>, Hornicek FJ, Mankin HJ, Raskin KA. &ldquo;Soft Tissue Sarcoma Resection Volume Associated with Wound-Healing Complications,&rdquo; <em>Clinical Orthopaedics and Related Research.</em> 2007; 457:182-5.</li>
<li>Ames JA, Abraham JA, <strong>Geller DS</strong>, Goldsmith J, Gebhardt MC.&nbsp; Proximal Tibial Lesion in a Young Adult: Early Diagnosis Allowing Unique Reconstruction.&nbsp; <em>The Orthopaedic Journal at Harvard Medical School.</em> 2006 Aug: 143-7.</li>
<li>Gardner MJ, Yacoubian S, <strong>Geller DS</strong>, Pode M, Mintz D, Helfet&nbsp; DL,&nbsp; Lorich DG. &ldquo;Prediction of Soft-Tissue Injuries in Schatzker II Tibial Plateau Fractures based on Measurements of Plain Radiographs,&rdquo; <em>Journal of Trauma-Injury Infection &amp; Critical Care</em>. 2006; 60(2):319-324.</li>
<li>Steinberg EL, <strong>Geller DS</strong>, Yacoubian SV, Shasha N, Dekel S, Lorich DG. &ldquo;Intramedullary Fixation of Tibial Shaft Fractures Using an Expandable Nail,&rdquo; <em>Journal of Orthopaedic Trauma.&nbsp; </em>2006 May; 20(5):303-9.</li>
<li>Gardner, MJ, Yacoubian S, <strong>Geller DS</strong>, Suk M, Mintz D, Potter H, Helfet DL, Lorich DG. &ldquo; The Incidence of Soft Tissue Injury in Operative Tibial Plateau Fractures,&rdquo; <em>Journal of Orthopaedic Trauma</em>.&nbsp; 2005; 19:79-84.</li>
<li>Lorich DG, Yacoubian SV, <strong>Geller DS</strong>. &ldquo;Intramedullary Fixation of Humeral Shaft Fractures Using an Inflatable Nail,&rdquo; <em>Orthopaedics</em>. 2003 Oct; 26(10):1011-4.</li>
<li>Lorich DG, <strong>Geller DS</strong>, Yacoubian SV, Leo AJ, Helfet DL. &ldquo;An Innovative Mode of Intramedullary Fixation,&rdquo; <em>International Review of Modern Surgery</em>, March 2002.</li>
<li>Westrich GH, <strong>Geller DS</strong>, O&rsquo;Malley MJ, Deland JT, Helfet DL. &ldquo;Anterior Iliac Crest Bone Graft Harvesting Using the Cortico-Cancellous Reamer System,&rdquo; <em>Journal of Orthopaedic Trauma</em>. 2001 Sep-Oct; 15(7):500-6.</li>
</ul>

EMR ID

4324

Biography

<p>David S. Geller is a board-certified orthopedic oncologist who specializes in the treatment of both pediatric and adult patients with bone and soft-tissue tumors. He has been a full-time faculty member at Montefiore since 2006. He is an Associate Professor of Orthopedic Surgery and Pediatrics at our Albert Einstein College of Medicine.</p><p>Dr. Geller is known for his expertise in musculoskeletal tumor surgery, with specific experience in bone and soft-tissue sarcomas, such as osteosarcoma, Ewing's sarcoma, liposarcoma and synovial sarcoma. He has extensive experience in managing patients with metastatic carcinoma of the bone as well. He routinely offers limb-salvage surgery using a wide array of reconstructive tools.</p><p>Dr. Geller earned his medical degree from Tel Aviv University's Sackler School of Medicine and completed an orthopedic surgery residency at Montefiore. He received his fellowship training from the Harvard Combined Orthopedic Oncology Program, which included Massachusetts General Hospital, Boston Children's Hospital, and Beth Israel Deaconess Medical Center.</p><p>Dr. Geller serves as the Associate Director of the Musculoskeletal Oncology Research Laboratory at Montefiore. He leads numerous translational research efforts designed to investigate the pathophysiology and molecular mechanisms of bone and soft tissue cancers. He is interested in improved surgical techniques and novel therapeutic approaches for primary malignant bone tumors. He is actively involved in collaborative clinical trials both nationally and internationally.</p><p>Dr. Geller is an active member of the American Academy of Orthopedic Surgeons, Muskuloskeletal Tumor Society, Connective Tissue Oncology Society, Children's Oncology Group, American Orthopedic Association, and the American Association for Cancer Research.</p>

Is Open Scheduling

Off

Madhur K. Garg

https://assets.montefioreeinstein.org/profiles/images/8782-madhur-garg.jpg

First Name

Madhur

Last Name

Garg

NPI

1215018643

Faculty ID

8782

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<dl id="header_01" class="detail">
<dd id="biography">
<p>Dr. Garg is the Clinical Director of Radiation Oncology, Director of Montefiore-Einstein's Proton Therapy Program and Co-Director of Stereotactic Radiation Therapy Program at Montefiore Medical Center.</p>
<p>He earned his medical degree at King George&rsquo;s Medical College and completed his residency in radiation oncology at Rush-Presbyterian-St. Luke&rsquo;s Hospital in Chicago and Montefiore in New York City. He also completed a specialized fellowship at Wayne State University in Detroit.</p>
<p>Dr. Garg is the recipient of the prestigious American Society of Clinical Oncology&rsquo;s Young Investigator's Award and the Department of Defense Physician Research Award. He is listed as one of the &ldquo;New York Top Doctors,&rdquo; &ldquo;America&rsquo;s Top Oncologists&rdquo; and &ldquo;Best Doctors in America.&rdquo;</p>
<p>Dr. Garg serves on several Montefiore and Einstein committees, as well as international societies such as the American Society of Clinical Oncology, the American College of Radiology and the American Society for Radiation Oncology. He is on the review boards for several journals, including&nbsp;<em>International Journal of Radiation Oncology &bull; Biology &bull; Physics</em>.</p>
<p>Dr. Garg is a principal investigator of several national and international research studies involving novel cancer treatment modalities and is actively involved in quality of life and healthcare issues for cancer patients.</p>
<p>His areas of interest are as below:</p>
</dd>
</dl>
<p>1. Advanced Technologies in Radiation Oncology (IMRT and IGRT)</p>
<p>2. Stereotactic Radiosurgery (SRS) for brain and spinal cord tumors</p>
<p>3.Proton Therapy and Particle Therapy</p>
<p>4. Stereotactic Body Radiation Therapy (SBRT) for lung and liver malignancies</p>
<p>5. Functional imaging and adaptive planning for Head/Neck malignancies</p>
<p>6. Translational research involving role of Anti-Angiogenensis and Immunotherapy in radiation therapy</p>
<p>7. Addressing Disparties in Cancer Care</p>
<p>8. Diet, Nutrition and Cancer</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Advanced technologies in radiation oncology with a focus on stereotactic targeting, functional imaging and adaptive planning.

Research Focus

Translational research involving anti-angiogenesis and radiosensitivity. Dr. Garg is a principal investigator of several national and international research studies involving novel cancer treatment modalities and is actively involved in quality of life for cancer patients.

Elsevier Profile

Selected Publications

<p><strong>1. Garg MK</strong>, Tekyi-Mensah S, Bolton S, Velasco J, Pontes E, Wood Jr DP, Porter AT, Forman JD: <em>The impact of Post-Prostatectomy PSA nadir on outcomes&nbsp;&nbsp; following salvage radiotherapy</em>.&nbsp; Urology 1998; 51(6): 998-1002.</p>
<p>&nbsp; &nbsp; &nbsp; &nbsp;<br />2. Guha C, Parashar B, Deb NJ, <strong>Garg MK</strong>, Gorla GR, Singh A, Roy-Chowdhury N, Vikram B, Roy-Chowdhury J: <em>Normal hepatocytes correct serum bilirubin after repopulation of Gunn rat liver subjected to irradiation/partial resection</em>. Hepatology, 2002; 36: 354-62.<br />&nbsp;<br />3. Sood B, <strong>Garg MK</strong>, Avadhani J, Gorla G, Malhotra H, Deore S, Vikram B: <em>Predictive value of Linear Quadratic Model in the treatment of Cervix Cancer using High Dose Rate Brachytherapy. </em>Int J Radiat Oncol Biol Phys 2002; 54(5): 1377-1387.</p>
<p><strong>4. Garg MK</strong>, Yaparpalvi R, Beitler JJ: <em>Loss of Cervical Spinal Curvature during radiation therapy for head and neck cancers. </em>Int J Radiat Oncol Biol Phys 2004; 58(1):185-188.<br />&nbsp;</p>
<p><strong>5.Garg MK, </strong>Beitler JJ:&nbsp; <em>Controversies in management of neck in head and neck cancer. </em>Curr Treat Options Oncol 2004; 5(1): 35-40.<br />&nbsp;</p>
<p><strong>6.Garg MK</strong>, Sharma A, Gorla G, Jaggernauth W, Beitler, JJ: <em>Role of High Dose Rate Brachytherapy in management of Recurrent Keloids after Surgery and External Beam Radiation therapy. </em>Radiother Oncol 2004; 73(2): 233-236.</p>
<p>7. Novetsky A, Einstein M, Goldberg G, Hailpern S, Landau E, Fields A, Mutyala M, Kalnicki S, <strong>Garg MK</strong><em>: </em><em>Efficacy And Toxicity Of Concomitant Cisplatin With External Beam Pelvic Radiotherapy And Two High Dose Rate Brachytherapy Insertions For The Treatment Of Locally-Advanced Cervical Cancer</em>. Radiother Oncol. 2004 Nov;73(2):233-6.</p>
<p>8. Beitler JJ, <strong>Garg MK,</strong> Ahn A, Owen R, Smith R: &ldquo;<em>High Dose Rate (HDR) Brachytherapy plus Neck Dissection for Nodal Disease&rdquo;</em> Head Neck. 2008 Mar 7; [Epub ahead of print]<br />&nbsp;</p>
<p>9. A Mukhopadhaya, J Mendecki, X Dong, L Liu, S Kalnicki, <strong>M Garg,</strong> A Alfieri, C Guha: &ldquo;<em>Localized Hyperthermia Combined with Intratumoral Dendritic Cells Induces Systemic Antitumor Immunity&rdquo;. </em>Cancer Res. 2007 Aug 15;67(16):7798-806.<br />&nbsp;</p>
<p>10. J Belbin, A Bergman, M Brandwein-Gensler, Q Chen, G Childs, <strong>M Garg,</strong> M Haigentz, R Hogue-Angeletti, R Moadel, A Negassa, R Owen, MB Prystowsky¹, B Schiff, NF Schlecht, K Shifteh, RV Smith, X Zheng: <em>&ldquo;Head and Neck Cancer: Reduce and Integrate for Optimal Outcome.&rdquo; </em>Genes Genet Syst. 2007 Oct;82(5):403-8.<br />&nbsp;</p>
<p>11. Peter H. Ahn, MD and <strong>Madhur K. Garg, MD</strong>: &ldquo;<em>PET-CT in head and neck cancers for target delineation</em>.&rdquo; Semin Nucl Med. 2008 Mar;38(2):141-8.<br /><strong>&nbsp;</strong>Yaparpalvi R, Mutyala S, Gorla GR, Butler J, Mah D, <strong>Garg MK</strong>, Kalnicki S. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18782683?ordinalpos=3&amp;itool=Entr… vs. volumetric bladder and rectal doses in combined intracavitary-interstitial high-dose-rate brachytherapy: correlation and comparison with published Vienna applicator data.</a> Brachytherapy. 2008 Oct-Dec;7(4):336-42. Epub 2008 Sep 7.<br />&nbsp;</p>
<p>12. Ahn PH, Ahn AI, Lee CJ, Shen J, Miller E, Lukaj A, Milan E, Yaparpalvi R, Kalnicki S, <strong>Garg MK.</strong> &ldquo;<em><a href="http://www.ncbi.nlm.nih.gov/pubmed/19147027?ordinalpos=1&amp;itool=Entr… positional variation among the skull, mandible, and cervical spine with treatment progression during head-and-neck radiotherapy&rdquo;.</a></em> Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):626-33.<br />&nbsp;</p>
<p>13. Hong LX, Chen CC, <strong>Garg M,</strong> Yaparpalvi R, Mah D. &ldquo;<em><a href="http://www.ncbi.nlm.nih.gov/pubmed/19147020?ordinalpos=2&amp;itool=Entr… experiences with onboard imager KV images for linear accelerator-based stereotactic radiosurgery and radiotherapy setup.</a>&rdquo;</em> Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):556-61.<br />&nbsp;</p>
<p>14. Skinner WK, Muse ED, Yaparpalvi R, Guha C, <strong>Garg MK,</strong> Kalnicki S. <em>&ldquo;<a href="http://www.ncbi.nlm.nih.gov/pubmed/19854386">Obtaining normal tissue constraints using intensity modulated radiotherapy (IMRT) in patients with oral cavity, oropharyngeal, and laryngeal carcinoma.</a></em>&rdquo; Med Dosim. 2009 winter; 34(4):279-84. Epub 2008 Dec 26<br />&nbsp;</p>
<p>15. Lee CC, Wu A, <strong>Garg M,</strong> Mutyala S, Kalnicki S, Sayed G, Mah D <em>&ldquo;<a href="http://www.ncbi.nlm.nih.gov/pubmed/20004563">A new approach to reduce number of split fields in large field IMRT.</a>&rdquo;</em> Med Dosim. [Epub ahead of print]<br />&nbsp;</p>
<p>16. Chen CC, Lee CC, Mah D, Sharma R, Landau E, <strong>Garg M,</strong> Wu A. <em>&ldquo;<a href="http://www.ncbi.nlm.nih.gov/pubmed/20202815">Dose sparing of brainstem and spinal cord for re-irradiating recurrent head and neck cancer with intensity-modulated radiotherapy.</a></em>&rdquo; Med Dosim. 2010 Mar 3. [Epub ahead of print]<br />&nbsp;</p>
<p>17. Quon H, Yom SS, <strong>Garg MK,</strong> Lawson J, McDonald MW, Ridge JA, Saba N, Salama J, Smith R, Yeung AR, Beitler JJ <em>&ldquo;<a href="http://www.ncbi.nlm.nih.gov/pubmed/20541056">ACR Appropriateness Criteria: local-regional therapy for resectable oropharyngeal squamous cell carcinomas.</a></em>&rdquo;Curr Probl Cancer. 2010 May-Jun;34(3):175-92. Review<br />&nbsp;</p>
<p>18. C. R. Salazar, R. V. Smith, <strong>M. Garg,</strong> M. Haigentz Jr., B. Schiff, N. Kawachi, J. Ostoloza, T. J. Belbin, M. B. Prystowsky, R. D. Burk, N. F. Schlecht : <em>&ldquo;Human papillomavirus associated survival and response to therapy in head and neck squamous cell carcinoma&rdquo;</em> Manuscript submitted to Annals of Oncology.<br />&nbsp;</p>
<p>19. Expert Panel on Radiation Oncology-Head and Neck, Salama JK, Saba N, Quon H, <strong>MK</strong> <strong>Garg,</strong> Lawson J, McDonald MW, Ridge JA, Smith RV, Yeung AR, Yom SS, Beitler JJ. <em>ACR appropriateness criteria&reg; adjuvant therapy for resected squamous cell carcinoma of the head and neck.</em> Oral Oncol. 2011 Jul;47(7):554-9. Epub 2011 Jun 12.</p>
<p>20. McDonald MW, Lawson J, <strong>Garg MK,</strong> Quon H, Ridge JA, Saba N, Salama JK, Smith RV, Yeung AR, Yom SS, Beitler JJ; Expert Panel on Radiation Oncology-Head and Neck Cancer. <em>ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer.</em> Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1292-8. Epub 2011 Apr 27. Review.&nbsp;<br />&nbsp;</p>
<p>21. Hong LX, <strong>Garg M,</strong> Lasala P, Kim M, Mah D, Chen CC, Yaparpalvi R, Mynampati D, Kuo HC, Guha C, Kalnicki S. <em>Experience of micromultileaf collimator linear accelerator based single fraction stereotactic radiosurgery: tumor dose inhomogeneity, conformity, and dose fall off. </em>Med Phys. 2011 Mar;38(3):1239-47</p>
<p>22. Ahn PH, Chen CC, Ahn AI, Hong L, Scripes PG, Shen J, Lee CC, Miller E,Kalnicki S, <strong>Garg MK.</strong> <em>Adaptive planning in intensity-modulated radiation therapy for head and neck cancers: single-institution experience and clinical implications</em>. Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):677-85. Epub 2010 Jul 9.</p>
<p>23. Saini G, Aggarwal A, Chomal M, Srivastava R, Sharma PK, Nangia S, Garg M<em>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21981875">Cranio-spinal irradiation with volumetric modulated arc therapy: a multi-institutional treatment experience.</a> </em>Radiother Oncol. 2012 Feb;102(2):322; Epub 2011 Oct 6.</p>
<p>24. Yeung AR, Garg MK, Lawson J, McDonald MW, Quon H, Ridge JA, Saba N, Salama JK, Smith RV, Yom SS, Beitler JJ; <em><a href="http://www.ncbi.nlm.nih.gov/pubmed/22250010">ACR Appropriateness Criteria&reg; ipsilateral radiation for squamous cell carcinoma of the tonsil.</a> </em>Expert Panel on Radiation Oncology--Head &amp; Neck Cancer American College of Radiology. Head Neck. 2012 May;34(5):613-6. doi: 10.1002/hed.21993. Epub 2012 Jan 17.</p>
<p>25. Garg MK, Glanzman J, Kalnicki S. <em><a href="http://www.ncbi.nlm.nih.gov/pubmed/22840597">The evolving role of positron emission tomography-computed tomography in organ-preserving treatment of head and neck cancer.</a> </em>Semin Nucl Med. 2012 Sep;42(5):320-7. doi: 10.1053/j.semnuclmed.2012.04.005. Review.</p>
<p>26. Garg MK, Ridge JA, Yom SS, McDonald MW, Quon H, Smith RV, Yeung AR, Lawson J, Saba N, Salama JK, Beitler JJ. <em>Reply, contralateral irradiation for T(limited)N2bM0 lateralized tonsil cancer.</em> Head Neck. 2013 Mar;35(3):465-6. doi: 10.1002/hed.23212. Epub 2013 Feb 5. No abstract available.<br />&nbsp;</p>
<p>27. Ohri N, Garg MK, Aparo S, Kaubisch A, Tome W, Kennedy TJ, Kalnicki S, Guha C.<em>Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis.&nbsp; </em>Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):330-5. doi: 10.1016/j.ijrobp.2013.02.008. Epub 2013 Mar 20. Review.<br />&nbsp;</p>
<p>28. Gez E, Cytron S, Ben Yosef R, London D, Corn BW, Alani S, Scarzello G, Dal Moro F, Sotti G, Zattoni F, Koziol I, Torre T, Bassignani M, Kalnicki S, Ghavamian R, Blakaj D, Anscher M, Sommerauer M, Jocham D, Melchert C, Huttenlocher S, Kovacs G, Garg M. <em>Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study.</em> Radiat Oncol. 2013 Apr 23;8:96. doi: 10.1186/1748-717X-8-96.<br />&nbsp;</p>
<p>29. Mourad WF, Young BM, Young R, Blakaj DM, Orhi N, Shourbaji RA, Manolidis S, G&aacute;mez M, Kumar M, Khorsandi A, Khan MA, Shasha D, Blakaj A, Glanzman J, Garg MK, Hu KS, Kalnicki S, Harrison LB. <em>Clinical validation and applications for CT-based atlas for contouring the lower cranial nerves for head and neck cancer radiation therapy. </em>Oral Oncol. 2013 Sep;49(9):956-63. doi: 10.1016/j.oraloncology.2013.03.449. Epub 2013 Apr 25.<br />&nbsp;</p>
<p>30. Ridge JA, Lawson J, Yom SS, Garg MK, McDonald MW, Quon H, Saba N, Salama JK, Smith RV, Worden F, Yeung AR, Beitler JJ. <em>American College of Radiology Appropriateness Criteria(&reg;) treatment of stage I T1 glottic cancer.</em> Head Neck. 2014 Jan;36(1):3-8. doi: 10.1002/hed.23381. Epub 2013 Sep 18. Review.</p>
<p>31. Einarson TR, Zilbershtein R, Skoup&aacute; J, Vesel&aacute; S, Garg M, Hemels ME. <em>Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic. </em>J Med Econ. 2013 Sep;16(9):1089-95. doi: 10.3111/13696998.2013.820193. Epub 2013 Jul 9.&nbsp;<br />&nbsp;</p>
<p>32. Mourad WF, Blakaj DM, Kabarriti R, Young R, Shourbaji RA, Glanzman J, Patel S, Yaparpalvi R, Kalnicki S, Garg MK. <em>Lack of adjuvant radiotherapy may increase risk of retropharyngeal node recurrence in patients with squamous cell carcinoma of the head and neck after transoral robotic surgery.</em> Case Rep Oncol Med. 2013;2013:727904. doi: 10.1155/2013/727904. Epub 2013 Jun 13.<br />&nbsp;</p>
<p>33. Salazar CR, Smith RV, Garg MK, Haigentz M Jr, Schiff BA, Kawachi N, Anayannis N, Belbin TJ, Prystowsky MB, Burk RD, Schlecht NF. <em>Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment.</em> Head Neck Pathol. 2014 Mar;8(1):77-87. doi: 10.1007/s12105-013-0486-4. Epub 2013 Sep 4.<br />&nbsp;</p>
<p>34. Mourad WF, Young R, Kabarriti R, Blakaj DM, Shourbaji RA, Glanzman J, Patel S, Ohri N, Yaparpalvi R, Beitler JJ, Kalnicki S, Garg MK. <em>25-year follow-up of HIV-positive patients with benign lymphoepithelial cysts of the parotid glands: a retrospective review. </em>Anticancer Res. 2013 Nov;33(11):4927-32.<br />&nbsp;</p>
<p>35. Salazar CR, Anayannis N, Smith RV, Wang Y, Haigentz M Jr, Garg M, Schiff BA, Kawachi N, Elman J, Belbin TJ, Prystowsky MB, Burk RD, Schlecht NF. <em>Combined P16 and human papillomavirus testing predicts head and neck cancer survival. </em>Int J Cancer. 2014 Nov 15;135(10):2404-12. doi: 10.1002/ijc.28876. Epub 2014 Apr 17.<br />&nbsp;</p>
<p>36. Salama JK, Golden DW, Yom SS, Garg MK, Lawson J, McDonald MW, Quon H, Ridge JA, Saba N, Smith RV, Worden F, Yeung AR, Beitler JJ. <em>ACR Appropriateness Criteria&reg; thyroid carcinoma.</em> Oral Oncol. 2014 Jun;50(6):577-86. doi: 10.1016/j.oraloncology.2013.12.004.<br />&nbsp;</p>
<p>37. Kawashita Y, Deb NJ, Garg MK, Kabarriti R, Fan Z, Alfieri AA, Roy-Chowdhury J, Guha C. <em>An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.</em> Radiat Res. 2014 Aug;182(2):201-10. doi: 10.1667/RR13617.1. Epub 2014 Jul 3.<br />&nbsp;</p>
<p>38. Kawashita Y, Deb NJ, Garg M, Kabarriti R, Alfieri A, Takahashi M, Roy-Chowdhury J, Guha C. <em>An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 1. Flt3 ligand gene transfer increases antitumor effects of a radio-inducible suicide gene therapy in an ectopic tumor model.</em> Radiat Res. 2014 Aug;182(2):191-200. doi: 10.1667/RR13594.1. Epub 2014 Jun 27.<br />&nbsp;</p>
<p>39. Yaparpalvi R, Mehta KJ, Bernstein MB, Kabarriti R, Hong LX, Garg MK, Guha C, Kalnicki S, Tom&eacute; WA. <em>Contouring and constraining bowel on a full-bladder computed tomography scan may not reflect treatment bowel position and dose certainty in gynecologic external beam radiation therapy.</em> Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):802-8. doi: 10.1016/j.ijrobp.2014.07.016. Epub 2014 Sep 20.<br />&nbsp;</p>
<p>40. Kabarriti R, Ohri N, Hannan R, Tishbi N, Baliga S, McGovern KP, Mourad WF, Ghavamian R, Kalnicki S, Guha C, Garg MK. <em>Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure. </em>Pract Radiat Oncol. 2014;4(6):409-14. doi: 10.1016/j.prro.2014.01.002. Epub 2014 Feb 22.<br />&nbsp;</p>
<p>41. Hong LX, Shankar V, Shen J, Kuo HC, Mynampati D, Yaparpalvi R, Goddard L, Basavatia A, Fox J, Garg M, Kalnicki S, Tom&eacute; WA. <em>Spine stereotactic body radiation therapy plans: Achieving dose coverage, conformity, and dose falloff.</em> Med Dosim. 2014 Dec 10. pii: S0958-3947(14)00125-3. doi: 10.1016/j.meddos.2014.11.002. [Epub ahead of print]</p>
<p>42. Ohri N, Rapkin BD, Guha D, Haynes-Lewis H, Guha C, Kalnicki S, Garg M. <em>Predictors of radiation therapy noncompliance in an urban academic cancer center. </em>Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):232-8. doi: 10.1016/j.ijrobp.2014.09.030.<br />&nbsp;Ow TJ, Pitts CE, Kabarriti R, Garg MK. <em>Effective Biomarkers and Radiation Treatment in Head and Neck Cancer. </em>Arch Pathol Lab Med. 2015 Jun 5. [Epub ahead of print]</p>
<p>43. Kabarriti R, Mark, D, Garg, MK.<em> Proton therapy for the treatment of pediatric head and neck cancers: a review. </em>J Ped Otorhinolaryng 2105 [in Press]</p>
<p><br />&nbsp;44. Paul B. Romesser, Oren Cahlon,Eli D. Scher, Eugen B. Hug,Kevin Sine, Carl DeSelm, Jana L. Fox, Dennis Mah, Madhur K. Garg, John Han-Chih Chang, and Nancy Y. Lee:<em> &ldquo;Proton Beam Re-Irradiation for Recurrent Head and Neck Cancer: Multi-Institutional Report on Feasibility and Early Outcomes&rdquo;:</em>Int J Radiat Oncol Biol Phys. 2015 (in press)</p>

EMR ID

4254

Biography

<p>Madhur Garg earned his medical degree at King George&rsquo;s Medical College and completed his residency in radiation oncology at Rush-Presbyterian-St. Luke&rsquo;s Hospital in Chicago and Montefiore in New York City. He also completed a specialized fellowship at Wayne State University in Detroit.</p><p>Dr. Garg is the recipient of the prestigious American Society of Clinical Oncology&rsquo;s Young Investigator's Award and the Department of Defense Physician Research Award. He is listed as one of the &ldquo;New York Top Doctors,&rdquo; &ldquo;America&rsquo;s Top Oncologists&rdquo; and &ldquo;Best Doctors in America.&rdquo;</p><p>Dr. Garg serves on several Montefiore and Einstein committees, as well as international societies such as the American Society of Clinical Oncology, the American College of Radiology and the American Society for Radiation Oncology. He is on the review boards for several journals, including <em>International Journal of Radiation Oncology &bull; Biology &bull; Physics</em>.</p>

Is Open Scheduling

Off